Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal
Show more: Authors information and Publication history
Authors Information
1 Immunoallergology Department, Santa Maria Hospital, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
2 Universitary Center of Immunoalergology, Medicine Faculty of Lisbon, Lisbon, Portugal
History
:
Published online: 16 January 2018
Accepted: 12 December 2017
Received: 2 April 2017
SUMMARY
Objective. Describe the safety and long-term use of omalizumab in chronic urticaria (CU), both spontaneous (CSU) and inducible (CIndU). Methods. Retrospective chart-review (2006-15) of CU patients treated with omalizumab for >/= 6 months. Statistical analyses: descriptive statistics, Mann-Whitney, generalized linear models. Results. 23 patients with CSU (3 men), 3 with CIndU (2 men). Generalized linear models showed UAS reduction per omalizumab administration of 16% in CIndU and CSU (both p < 0.001) and UAS7, of 15% in CIndU, and 20% in CSU (both p < 0.001). DLQI score at baseline had a median of 19 (CIndU and CSU) and after omalizumab a median of 0 (in both). Seven CSU patients stopped omalizumab and remain asymptomatic. No side-effects were observed. Conclusion. Omalizumab is safe and efficacious in CU. Stopping omalizumab can be tried, as some patients achieve remission.
